At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Type 2 Diabetes diagnosed ≥180 days before screening
- ✓HbA1c 7-9% at screening
- ✓On daily basal insulin for ≥90 days
- ✕Hypersensitivity to Degludec
- ✕Current use of an insulin pump
- ✕Current use of short-acting insulin
- ✕Participation in another trial within 90 days of screening
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory 16-Week Pilot Study of the Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin, With or Without Non-Insulin Antidiabetic Drugs, in Type 2 Diabetes Mellitus Participants Treated With Basal Insulin.
In Brief
A clinical study evaluating Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs for Type 2 Diabetes. Completed, enrolled 30 participants across 2 sites.
Detailed Summary
The goal of this clinical trial is to compare the effect of a continuous glucose monitor (CGM) based titration algorithm to standard titration by self-monitoring blood glucose (SMBG) in participants with Type 2 Diabetes already using long acting insulin. The comparison aims to study the difference in glycemic control between the two therapies. Participants will be followed for 18 weeks and will be provided with Degludec insulin, insulin pen, and a CGM (Dexcom G6).
Study Details
Timeline
Interventions
A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform